AbstractGlioblastoma multiforme (GBM) is the most common and aggressive primary neoplasm of the brain. Poor prognosis is mainly attributed to tumor heterogeneity, invasiveness, and drug resistance. microRNA-based therapeutics represent a promising approach due to their ability to inhibit multiple targets. In this work, we aim to restore the oncosuppressor activity of microRNA-34a (miR-34a) in GBM. We developed a cationic carrier system, dendritic polyglycerolamine (dPG-NH2), which remarkably improves miRNA stability, intracellular trafficking, and activity. dPG-NH2 carrying mature miR-34a targets C-MET, CDK6, Notch1 and BCL-2, consequently inhibiting cell cycle progression, proliferation and migration of GBM cells. Following complexation wi...
Abstract Background Glioblastoma multiforme (GBM) ...
Despite our growing molecular-level understanding of glioblastoma (GBM), treatment modalities remain...
Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated...
AbstractGlioblastoma multiforme (GBM) is the most common and aggressive primary neoplasm of the brai...
Glioblastoma is a rapidly progressing tumor quite resistant to conventional treatment. These feature...
Glioblastoma (GBM) is the most common and deadly form of malignant brain tumor in the United States,...
Neuroblastoma (NB) tumor substantially contributes to childhood cancer mortality. The design of nove...
Abstract Glioblastoma (GBM) is the most common malignant brain tumor. Available treatments have limi...
A minor population of glioblastoma stem-like cells (GSCs) has been implicated in the relapse and res...
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite progress in surgica...
Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgent...
Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the hi...
Glioblastoma are aggressive brain tumours with a median survival of 15 months even with the best cur...
The cancer stem cell (CSC) hypothesis postulates that cancer cells overexpressing CD44 are marked as...
Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgent...
Abstract Background Glioblastoma multiforme (GBM) ...
Despite our growing molecular-level understanding of glioblastoma (GBM), treatment modalities remain...
Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated...
AbstractGlioblastoma multiforme (GBM) is the most common and aggressive primary neoplasm of the brai...
Glioblastoma is a rapidly progressing tumor quite resistant to conventional treatment. These feature...
Glioblastoma (GBM) is the most common and deadly form of malignant brain tumor in the United States,...
Neuroblastoma (NB) tumor substantially contributes to childhood cancer mortality. The design of nove...
Abstract Glioblastoma (GBM) is the most common malignant brain tumor. Available treatments have limi...
A minor population of glioblastoma stem-like cells (GSCs) has been implicated in the relapse and res...
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite progress in surgica...
Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgent...
Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the hi...
Glioblastoma are aggressive brain tumours with a median survival of 15 months even with the best cur...
The cancer stem cell (CSC) hypothesis postulates that cancer cells overexpressing CD44 are marked as...
Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgent...
Abstract Background Glioblastoma multiforme (GBM) ...
Despite our growing molecular-level understanding of glioblastoma (GBM), treatment modalities remain...
Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated...